Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those that follow publicly traded cannabis companies.
Curaleaf Completes $16m Acquisition of Northern Green Canada
Curaleaf has finalised its $16m acquisition of Canadian cannabis producer Northern Green Canada (NGC), helping the company secure its foothold...